β-L-ara-A | 63267-73-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: β-L-ara-A
• 英文别名: 9-(α-L-arabinofuranosyl)adenine；9-(beta-L-arabinofuranosyl)-9H-purin-6-amine；(2R,3R,4R,5S)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol；(1R)-1-(6-amino-purin-9-yl)-1,4-anhydro-L-arabitol；(1R)-1-(6-Amino-purin-9-yl)-1,4-anhydro-L-arabit；(2R,3R,4R,5S)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol；(2R,3R,4R,5S)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 63267-73-2
• 化学式: C₁₀H₁₃N₅O₄
• 分子量: 267.244
• InChiKey: OIRDTQYFTABQOQ-FCIPNVEPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  140
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  β-L-ara-A 在 溴 作用下， 以 水 为溶剂， 反应 24.0h， 以60%的产率得到8-bromo-9-(α-L-arabinofuranosyl)adenine
  参考文献：
  名称：

  8-Substituted Adenine β-D-Xylofuranosides and α-L-Arabinofuranosides

  摘要：

  9-(beta-D-Xylofuranosyl)adenine and 9-(alpha-L-arabinofuranosyl)adenine have been modified to give a series of gr-amino-substituted nucleosides. Convenient methods of halogenation of these nucleosides and reactions of 8-halogenated nucleosides with various amines are described. No significant cytotoxic or antiviral activity was found.

  DOI：

  10.1080/15257779508009752
• 作为产物：
  描述：

  N6-苯甲酰基腺嘌呤 在 ammonium hydroxide 、 四氯化锡 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 47.0h， 生成 β-L-ara-A
  参考文献：
  名称：

  8-Substituted Adenine β-D-Xylofuranosides and α-L-Arabinofuranosides

  摘要：

  9-(beta-D-Xylofuranosyl)adenine and 9-(alpha-L-arabinofuranosyl)adenine have been modified to give a series of gr-amino-substituted nucleosides. Convenient methods of halogenation of these nucleosides and reactions of 8-halogenated nucleosides with various amines are described. No significant cytotoxic or antiviral activity was found.

  DOI：

  10.1080/15257779508009752

文献信息

• [EN] MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS OLIGOMÈRES MODIFIÉS ET LEURS UTILISATIONS
  申请人：IONIS PHARMACEUTICALS INC

  公开号：WO2021030763A1

  公开（公告）日：2021-02-18

  The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard nucleoside. An oligomeric compound comprising a modified oligonucleotide consisting of 12-30 linked nucleosides, wherein at least one nucleoside of the modified oligonucleotide is a stereo-non-standard nucleoside; and wherein the oligomeric compound is selected from among an RNAi compound, a modified CRISPR compound, and an artificial mRNA compound.

  本公开提供了包含至少一种立体非标准核苷酸的修饰寡核苷酸的寡聚化合物。包括由12-30个连接的核苷酸组成的修饰寡核苷酸的寡聚化合物，其中修饰寡核苷酸的至少一个核苷酸是立体非标准核苷酸；且所述寡聚化合物选自RNAi化合物、修饰CRISPR化合物和人工mRNA化合物。
• [EN] SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS<br/>[FR] DIHYDROIMIDAZOPYRIDINEDIONES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE MKNK1 ET DE MKNK2
  申请人：BAYER PHARMA AG

  公开号：WO2018134148A1

  公开（公告）日：2018-07-26

  The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (A) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.

  本发明涉及通式（A）所描述和定义的取代二氢咪唑吡啶二酮化合物，以及制备该化合物的方法，用于制备该化合物的有用中间体化合物，包含该化合物的药物组合物和复合物，以及利用该化合物制造用于治疗或预防疾病的药物组合物，特别是治疗过度增殖、血管生成障碍、炎症性疾病或与炎症性疼痛相关的疾病的药物组合物，作为单一药剂或与其他活性成分结合使用。
• Synthesis and hybridization studies of α-configured arabino nucleic acids
  作者：Pankaj Gupta、Jyotirmoy Maity、Gaurav Shakya、Ashok K. Prasad、Virinder S. Parmar、Jesper Wengel

  DOI：10.1039/b905019c

  日期：——

  Synthesis of α-L-arabino- and α-D-arabino-configured pentofuranosyl nucleosides of four of the natural bases [thymine (ara-T), adenine (ara-A), cytosine (ara-C) and guanine (ara-G)] is reported together with hybridization properties of oligonucleotides containing α-L-ara-T and -A, α-D-ara-T and -A, and 2′-amino-α-L-ara-T monomers. 2′-O-Acetylated α-L-ara-T, -A, -C and -G, α-D-ara-T, -A, -C and -G,

  四个天然碱的α-L-阿拉伯糖和α-D-阿拉伯糖构型的呋喃呋喃糖基核苷的合成[胸腺嘧啶 （一只老鼠）， 腺嘌呤 （ara-A）， 胞嘧啶 （ara-C） 和 鸟嘌呤（ara-G）]与含有α-L-ara-T和-A，α-D-ara-T和-A以及2'-氨基-α-L-ara-T的寡核苷酸的杂交特性一起报道。单体。2' - O-乙酰化的α-L-ara-T，-A，-C和-G，α-D-ara-T，-A，-C和-G和N2'-酰化的α-L-合成了ara-T亚磷酰胺结构单元，并将其与标准DNA亚磷酰胺一起用于18-mer寡核苷酸的固相合成。热变性实验表明，掺入了三到六种阿拉伯糖-配置成DNA-寡核苷酸的单体降低了对反平行DNA / RNA补体的结合亲和力。完全修饰的α-L-ara-寡核苷酸不与DNA / RNA互补序列杂交，而证实了完全修饰的α-D-ara-寡核苷酸与互补DNA / RNA在平行链方向上的杂交。
• Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US11311520B2

  公开（公告）日：2022-04-26

  The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.

  本发明涉及本文所描述和定义的通式（I）的取代二氢咪唑吡啶二酮化合物，涉及制备所述化合物的方法，涉及用于制备所述化合物的中间体化合物，涉及包含所述化合物的药物组合物和组合物，还涉及使用所述化合物制造药物组合物，用于治疗或预防疾病，特别是过度增殖性疾病、血管生成障碍、炎症性疾病或与炎性疼痛相关的疾病，可作为单独制剂或与其他活性成分组合使用。
• Some Synthetic Analogs of the Natural Purine Nucleosides¹
  作者：John Davoll、Bertram A. Lowy

  DOI：10.1021/ja01126a066

  日期：1952.3